Articles tagged with Multiple Sclerosis
A new study by Penn and Dresden researchers has identified the protein Del-1 as a key player in blocking multiple sclerosis relapses in mice. The protein, also found to prevent inflammation and bone loss in gum disease, shows promise as a potential therapeutic target for treating neurodegenerative diseases.
A new study demonstrates that people with multiple sclerosis often have trouble recognizing emotions conveyed by facial expressions, and now shows similar difficulties with emotions expressed through body posture. The research suggests that this difficulty is unrelated to identifying one's own emotions, a disorder known as alexithymia.
A new study pinpoints the complex genetic origins of multiple autoimmune diseases, including type 1 diabetes and MS. The researchers discovered that specific DNA variations, even outside genes, can alter immune system functions. Epigenetic characteristics of immune cells were also found to play a crucial role in disease development.
Researchers developed a mathematical model to analyze data from genome-wide association studies, pinpointing genetic variants that cause autoimmune diseases. The study found strong links between the immune system and neurologic disease MS, suggesting a primary role of the immune system in causing the disease.
Researchers at EMBL found that IGF-1 enhances T-reg cell production, suppressing auto-immune diseases like type-1 diabetes and multiple sclerosis. The molecule is already approved for use in patients, paving the way for clinical trials.
The Weizmann Institute of Science has developed a novel, highly active interferon variant called YNSalpha8. PASylation technology extended its half-life in the body, resulting in improved protection from disease progression in a mouse model of human multiple sclerosis.
A recent study published in JAMA Neurology found no long-term link between vaccine administration and the development of multiple sclerosis (MS) or other central nervous system demyelinating syndromes. However, a short-term increased risk was observed in younger patients, which may be attributed to existing disease.
A large retrospective study found that nearly 60% of patients with both uveitis and multiple sclerosis (MS) are diagnosed with each condition within a five-year span. The study also revealed that MS is more likely to be diagnosed before or after uveitis, not simultaneously.
Dr. Lauren Strober will update the Symbol Digit Modalities Test (SDMT) to improve its use in clinical settings for individuals with Multiple Sclerosis (MS). The updated test will more accurately assess processing speed changes over time, enabling better prediction of disease progression and outcomes.
The Oklahoma Medical Research Foundation will receive a two-year $280,000 grant to investigate the role of BAFF and APRIL molecules in multiple sclerosis progression. This project aims to understand how inhibiting these molecules affects disease symptoms in experimental models.
Researchers found that patients with Multiple Sclerosis (MS) can safely tolerate treatment with cells cultured from human placental tissue. Early signals also suggest the potential for repairing damaged nerve tissues, offering a new frontier in treatment for the disease.
A 10-week psychoeducational wellness program improved mood, overall mental health, perceived stress, and pain in people with multiple sclerosis. The study, published in the International Journal of MS Care, suggests that individuals with MS may benefit from comprehensive wellness programs.
The International Progressive Multiple Sclerosis (MS) Alliance awarded a $30 million grant to researchers worldwide to tackle the devastating form of MS. Kessler Foundation's pilot study in rehabilitation addresses cognitive dysfunction, aiming to improve quality of life for individuals with progressive MS.
Kessler Foundation researchers have discovered a link between slowed processing speed and executive deficits in people with multiple sclerosis. The study found that slower processing speed accounted for the observed executive function deficits, suggesting a potential target for cognitive rehabilitation strategies.
A large-scale study found that more than 70% of individuals with multiple sclerosis screened positive for one or more sleep disorders, highlighting the importance of diagnosing and managing these conditions. The study's findings suggest that sleep problems may be a hidden epidemic in the MS population, separate from MS fatigue.
Researchers found that people with multiple sclerosis (MS) lose myelin in their gray matter, a characteristic of the disease that affects brain function. The study's findings suggest that gray matter demyelination is strongly related to MS disability and have important implications for treatment monitoring and clinical trials.
Researchers at Kessler Foundation found that working memory capacity explains the relationship between intellectual enrichment and long-term memory in individuals with MS. This suggests that interventions targeting working memory may help build cognitive reserve to protect against decline in long-term memory.
Researchers at Lund University discovered inflammation and changes in the intestinal barrier function early in MS, indicating a potential link to disease progression. The study suggests that damage to the intestinal barrier may prevent the body from ending an autoimmune reaction, leading to chronic diseases like MS.
Researchers at the University of Bristol have made a breakthrough in understanding how cells convert from attacking healthy tissue to protecting against disease. This discovery could lead to the development of a new treatment approach using antigen-specific immunotherapy, which may improve the lives of millions worldwide.
A study of 70 people with relapsing-remitting multiple sclerosis found that high dietary salt intake was associated with more episodes of worsening symptoms and a higher likelihood of radiological signs of disease progression. Vitamin D levels also played a role, with low levels linked to the disease.
A new treatment, anti-LINGO-1, has been found to be safe and tolerable in phase I clinical trials for multiple sclerosis. The treatment blocks a protein that prevents myelination, potentially repairing damaged nerves.
Researchers used functional near infrared spectroscopy (fNIRS) to examine brain activation during a working memory task in people with multiple sclerosis (MS) and healthy controls. The study found differences in brain activation patterns between the groups that were dependent on task load.
A new study published in Radiology found that using the Wii Balance Board system can induce favorable changes in brain connections associated with balance and movement in patients with multiple sclerosis. The device helps improve balance, reducing the risk of accidental falls and related comorbidities.
A new Kessler Foundation study reveals that people with multiple sclerosis (MS) can enhance their self-awareness through hands-on task experiences. Researchers found improved metacognitive knowledge and online awareness in participants, suggesting potential benefits for cognitive rehabilitation.
A new study identifies a novel gene, Inpp4b, that controls nerve conduction velocity and is linked to multiple sclerosis. The researchers found that polymorphisms in this gene affect nerve conduction speed in both mice with experimental autoimmune encephalomyelitis (EAE) and humans with MS.
Cognitive research by Kessler Foundation scientists reveals that unexpected task constraint following self-generated task choice impairs task-switching performance. The study shows that individuals struggle to undo preparation for a task, leading to negative effects on multitasking ability.
Researchers explore the link between gut microbiome and autoimmune disorders like multiple sclerosis, highlighting potential therapeutic targets. The study suggests that the gut microbiome plays a crucial role in immune cell activity and cytokine production, which may impact susceptibility to and treatment of autoimmune diseases.
Researchers at The New York Stem Cell Foundation have developed a new protocol to induce pluripotent stem cells into oligodendrocytes, the myelin-forming cells implicated in multiple sclerosis. This accelerated approach cuts production time almost in half, enabling researchers to study disease progression and develop potential treatments.
A new study reveals that microglia can increase neuronal firing and enhance brain cell survival after traumatic brain injury, potentially slowing the progression of neurodegenerative diseases. The research found that activated microglia dislodge inhibitory synapses, leading to increased firing and enhanced survival.
Researchers at the University at Buffalo have identified SOX10 as a key transcription factor that initiates myelination in human brain cells. This discovery brings researchers closer to developing a viral or pharmaceutical approach to inducing SOX10 in MS patients, which could lead to a more effective treatment for multiple sclerosis.
A longitudinal study of 22 MS patients found significant declines in cognitive function, including processing speed and memory, over an 18-year period. The study provides valuable insights into the natural evolution of cognitive changes in MS.
Human embryonic stem cell therapy has been shown to significantly reduce MS disease severity in animal models, offering a promising new treatment for the debilitating disease. The therapy also provides an unlimited source of high-quality mesenchymal stem cells, which can be propagated indefinitely in lab cultures.
A new report refines descriptions of multiple sclerosis (MS) courses, categorizing progressive relapsing as an active form of primary progressive MS. The updated definitions aim to enhance research, clinician-patient communication, and clinical trial design.
Researchers enrolled 120 MS patients and 60 healthy controls, finding no significant difference in diagnosed chronic cerebrospinal venous insufficiency between groups. The study's findings dispute the theory linking CSVI to MS due to methodological concerns and questionable diagnosis criteria.
Researchers at Mount Sinai Hospital have re-examined multiple sclerosis (MS) clinical course descriptions to provide a framework for both clinical research and ongoing clinical care. The proposed 2013 revisions include improved clinical descriptive terminology, MRI imaging, and analysis of fluid biomarkers.
Researchers have developed a new imaging technique to track Multiple Sclerosis (MS) progression from its earliest stages. The study uses QS Magnetic Resonance Imaging (MRI) to measure damage in specific brain areas, revealing that even at early disease stages, patients already show significant damage.
Dr. Ekaterina Dobryakova, a postdoctoral fellow at Kessler Foundation, received an award to study motivation's influence on cognitive fatigue in patients with multiple sclerosis (MS). The research aims to determine whether motivation activates brain regions thought to be impaired in cognitive fatigue.
Researchers found that human neural stem cells can repair damage caused by multiple sclerosis (MS) in mice, allowing them to walk again. The breakthrough has significant implications for developing a new treatment approach for MS patients.
Researchers at TSRI have developed a new stem cell therapy that shows promise for treating multiple sclerosis in humans. In a mouse model, the therapy resulted in significant recovery of mobility and function after implantation of human stem cells into the spinal cord.
Researchers found that females susceptible to MS produce higher levels of the blood vessel receptor protein S1PR2 than males, leading to the inflammation that causes MS. The study's findings have implications for developing new treatments, including a drug that disables S1PR2.
A new study reveals that leptin acts directly on neurons in the preoptic region of the hypothalamus to regulate peripheral levels of leutinizing hormone, essential for reproduction. The study demonstrates that leptin communicates the status of peripheral energy stores to GnRH-releasing neurons via the preoptic hypothalamus.
A low-fat diet may help alleviate fatigue in people with multiple sclerosis (MS). The study found that participants who followed a plant-based diet very low in saturated fat had significantly less fatigue at the end of the year compared to those who didn't follow the diet.
Researchers found that a new version of an old MS drug reduced patient relapses and lesion development by 36% compared to placebo. The updated formulation allowed for longer injection intervals, potentially increasing compliance and quality of life for MS patients.
A study confirms that brain reserve and cognitive reserve provide protective effects against cognitive decline in MS patients. The beneficial effects of these reserves persist for several years.
A clinical study of 158 patients with relapsing remitting multiple sclerosis (RRMS) found that combining Copaxone with estriol improved symptom reduction by 12 months, but the effect waned over time. The results suggest a potential benefit to supplementing Copaxone therapy with estrogen.
The American Academy of Neurology review found that medical marijuana can help treat spasticity, pain, and overactive bladder in multiple sclerosis patients. However, its effectiveness in other neurologic diseases such as Parkinson's, Huntington's, Tourette syndrome, cervical dystonia, and epilepsy remains uncertain.
A new study found that reducing B cell levels can significantly decrease brain lesions and disease activity in people with relapsing-remitting MS. The research showed that maintaining B cell levels below a threshold of 32-64 cells per microliter resulted in an annualized rate of less than one new brain lesion per year.
Nancy Chiaravalloti, PhD, was named the 63rd Mendel Lecturer by Saint Peter's University for her research on treating cognitive deficits following neurological illness and injury. Her work focuses on improving cognition in individuals with multiple sclerosis, TBI, stroke, and dementia.
The article provides evidence-based information on the latest treatments for multiple sclerosis, highlighting the benefits and risks of various therapies. Steroids are found to be the most effective way to treat relapses, while immunosuppressants like natalizumab and fingolimod have varying degrees of success.
Researchers will assess daily tasks like buying tickets and making food using the internet's Actual Reality platform. The goal is to broaden assessment scope for people with MS, making it more accessible and relevant.
Saint Louis University researcher Daniel Hawiger is awarded $608,376 to investigate immunological tolerance and its failures in multiple sclerosis (MS). He hopes to develop targeted therapies that selectively suppress immune-mediated damage without side effects.
Kessler Foundation will conduct a randomized controlled trial to examine the effectiveness of speed of processing training on cognitive performance in multiple sclerosis. The study aims to improve everyday functioning and address the impact of processing speed deficits on daily activities.
Researchers have discovered how new MS drug dimethyl fumarate works, blocking inflammatory cell infiltration in the central nervous system by targeting a specific receptor. The study found that DMF reduces neurological deficits in mice with multiple sclerosis-like symptoms.
The Kessler Foundation will lead a new MS Collaborative Network of New Jersey, focusing on cognitive-motor interactions in MS. The network aims to design and conduct novel studies and expand professional training to improve treatment options for people with MS.
The guideline states that certain forms of medical marijuana in pill or oral spray form may help reduce patients' reported spasticity symptoms, pain due to spasticity, and frequent urination. However, long-term safety of medical marijuana use is not known, and potential side effects include seizures, dizziness, and psychological problems.
Researchers found detectable JC virus DNA in at least one cell subtype of 26 out of 49 patients with MS starting natalizumab therapy. This study suggests that ongoing studies are needed to investigate the mechanism behind PML in natalizumab-treated MS patients.
Lauren Strober, a neuropsychologist at Kessler Foundation, has been awarded a $75,000 Patterson Trust Award to investigate factors influencing employment in individuals with multiple sclerosis. Her research aims to address the high rate of unemployment among MS patients and explore long-term outcomes associated with leaving the workforce.
A phase 2 study found that simvastatin slowed brain atrophy by 43% over two years compared to placebo. The medication was well-tolerated and showed small but significant improvements in disability scales.
Researchers found elevated body temperature linked to worse fatigue in patients with relapsing-remitting multiple sclerosis, supporting previous studies on cooling garments and antipyretics. The study suggests a complex relationship among fatigue, body temperature, and inflammatory processes.
A recent clinical trial has found that statins can slow the progression of advanced multiple sclerosis, a disease that gradually causes patients to become more disabled. The study showed that patients taking simvastatin achieved better scores on movement tests and questionnaires compared to those on a placebo.